Granules receives USFDA EIR for Chantilly plant

3 Jun 2026via Indian Pharma PostSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

Granules receives USFDA EIR for Chantilly plant — Granules India has received an Establishment Inspection Report (EIR) from the USFDA for its Chantilly, Virginia facility following a routine inspection. The EIR indicates no critical observations, a positive regulatory signal. This outcome supports future product approvals and export potential.

📊 STOCKS: GRANULES | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA

#USFDA#inspection#Granules

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →